Iconovo met innovation companies at BIO-Europe
Just recently, Iconovo has started to develop dry powder formulations for new drug candidates. In the interview from BIO-Europe, Roger Lassing points out that there are many interesting drug candidates that would benefit from delivery directly to the lungs, but where the research pharmaceutical company does not have an adequate solution for the administration. In such situations, Iconovo’s three inhaler platforms comes into play.
Furthermore, the interview touches on Iconovo’s recent collaboration agreement with British CrystecPharma, whose technologies will complement Iconovo’s in the joint development of comprehensive solutions for new innovative drugs in need of an optimal delivery to, or via, the lung. Read more.
Watch the full video interview with Roger Lassing, VP of Business Development at Iconovo, below.
The content of BioStock’s news and analyses is independent but the work of BioStock is to a certain degree financed by life science companies. The above article concerns a company from which BioStock has received financing.